Danish pharmaceutical company Novo Nordisk (NYSE: NVO) just made the headlines for something other than Ozempic. Well, sort of. One of the company's subsidiaries, Novo Holdings, is responsible for deploying capital in a mission-driven, efficient way to help broaden Novo Nordisk's reach.

Earlier this week, Novo Holdings announced it was acquiring for a total enterprise value of $16.5 billion. Let's break down the deal and analyze why this transaction could be a game changer for Novo Nordisk in the long run.

Catalent is a subcontractor for drug developers. Essentially, Catalent helps fulfill demand for treatments such as Ozempic and Wegovy at their various manufacturing facilities.

Continue reading

Source Fool.com